反応式
[Cl:1][C:2]1[CH:3]=[C:4]([C:8]2[C:13]3[N:14]([CH:17]([C@H:19]4[CH2:24][CH2:23][C@H:22]([CH3:25])[CH2:21][CH2:20]4)[CH3:18])[CH:15]=[N:16][C:12]=3[CH:11]=[C:10]([C:26]#[N:27])[N:9]=2)[CH:5]=[N:6][CH:7]=1.P([O-])([O-])(O)=O.[Na+].[Na+].[Br:35]N1C(C)(C)C(=O)N(Br)C1=O>C1COCC1>[Br:35][C:15]1[N:14]([C@H:17]([C@H:19]2[CH2:24][CH2:23][C@H:22]([CH3:25])[CH2:21][CH2:20]2)[CH3:18])[C:13]2[C:8]([C:4]3[CH:5]=[N:6][CH:7]=[C:2]([Cl:1])[CH:3]=3)=[N:9][C:10]([C:26]#[N:27])=[CH:11][C:12]=2[N:16]=1.[Br:35][C:15]1[N:14]([C@@H:17]([C@H:19]2[CH2:24][CH2:23][C@H:22]([CH3:25])[CH2:21][CH2:20]2)[CH3:18])[C:13]2[C:8]([C:4]3[CH:5]=[N:6][CH:7]=[C:2]([Cl:1])[CH:3]=3)=[N:9][C:10]([C:26]#[N:27])=[CH:11][C:12]=2[N:16]=1参加物
6
実験手順
Alternatively, racemic 4-(5-chloropyridin-3-yl)-3-[1-(trans-4-methylcyclohexyl)ethyl]-3H-imidazo[4,5-c]pyridine-6-carbonitrile (Step 2) was resolved into its enantiomers as described in Preparative Example 15.1 and brominated using the conditions described above or using the alternative conditions (disodium hydrogen phosphate and 1,3-dibromo-5,5-dimethylhydantoin in THF at 35° C., described in Example 2.1, Step 1 and Preparative Example 3.1, Step 3) to afford 2-bromo-4-(5-chloropyridin-3-yl)-3-[(1S)-1-(trans-4-methylcyclohexyl)ethyl]-3H-imidazo[4,5-c]pyridine-6-carbonitrile and 2-bromo-4-(5-chloropyridin-3-yl)-3-[(1R)-1-(trans-4-methylcyclohexyl)ethyl]-3H-imidazo[4,5-c]pyridine-6-carbonitrile.
出典と根拠
- ORDレコード
- ord-4b2fdae980dc41d2870b17120e338d9c
- 出典データセット
- uspto-grants-2015_02
- 特許番号
- US08962611B2
関連ノート
読み込み中…